The FDA cleared the Elecsys pTau217 blood test co-developed by Eli Lilly and Roche. This test identifies amyloid pathology markers in patients aged 55 and older experiencing cognitive decline.
The diagnostic tool provides a minimally invasive alternative to expensive PET scans and spinal taps. It is the first FDA-cleared single-biomarker test that can both rule in and rule out amyloid pathology.
Labcorp and Quest Diagnostics announced plans to offer the test to the public. These partnerships aim to make early Alzheimer's assessments more widely accessible.